Lite Strategy, Inc. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
Lite Strategy, Inc. (LITS) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $2.38 million as of 2025-06-30, per its 10-K filed 2025-09-26.
Financial Statements › Notes › Income Taxes › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2025-09-26
- 2025-06-30: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $2.38M.
- 2024-06-30: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $4.08M.
- 2023-06-30: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $5.15M.
- 2022-06-30: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $4.87M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2025-06-30 | $2.38M 10-K · filed 2025-09-26 |
| 2024-06-30 | $4.08M 10-K · filed 2025-09-26 |
| 2023-06-30 | $5.15M 10-K · filed 2024-09-19 |
| 2022-06-30 | $4.87M 10-K · filed 2023-09-26 |
| 2021-06-30 | $4.18M 10-K · filed 2022-09-08 |
| 2020-06-30 | $3.83M 10-K/A · filed 2022-05-23 |
| 2019-06-30 | $3.08M 10-K · filed 2020-09-09 |
| 2018-06-30 | $2.35M 10-K · filed 2019-08-28 |
| 2017-06-30 | $5.62M 10-K · filed 2018-08-30 |
| 2016-06-30 | $4.90M 10-K · filed 2017-09-05 |
| 2015-06-30 | $4.16M 10-K · filed 2016-09-06 |
| 2014-06-30 | $2.95M 10-K · filed 2015-09-02 |
| 2013-06-30 | $1.06M 10-K · filed 2014-09-09 |
| 2012-06-30 | $458.00K 10-K · filed 2013-09-18 |
| 2011-06-30 | $908.00K 10-K · filed 2012-09-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |